AR133953A1 - Inhibidores del factor b del complemento y usos de los mismos - Google Patents

Inhibidores del factor b del complemento y usos de los mismos

Info

Publication number
AR133953A1
AR133953A1 ARP240102601A ARP240102601A AR133953A1 AR 133953 A1 AR133953 A1 AR 133953A1 AR P240102601 A ARP240102601 A AR P240102601A AR P240102601 A ARP240102601 A AR P240102601A AR 133953 A1 AR133953 A1 AR 133953A1
Authority
AR
Argentina
Prior art keywords
complement factor
inhibitors
compounds
useful
formula
Prior art date
Application number
ARP240102601A
Other languages
English (en)
Inventor
Lara C Czabaniuk
Nina Gommermann
Konstanze Hurth
Sbastien Jacquier
Nancy Labbe-Giguere
Kaila Ashley Margrey
Martin Sendzik
Adeline Schoen
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR133953A1 publication Critical patent/AR133953A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos de la fórmula (1) y composiciones farmacéuticas de los mismos útiles para tratar enfermedades o trastornos mediados por el factor B del complemento.
ARP240102601A 2023-09-29 2024-09-26 Inhibidores del factor b del complemento y usos de los mismos AR133953A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363586620P 2023-09-29 2023-09-29

Publications (1)

Publication Number Publication Date
AR133953A1 true AR133953A1 (es) 2025-11-19

Family

ID=93284092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102601A AR133953A1 (es) 2023-09-29 2024-09-26 Inhibidores del factor b del complemento y usos de los mismos

Country Status (12)

Country Link
EP (1) EP4784563A1 (es)
KR (1) KR20260079630A (es)
CN (1) CN121925409A (es)
AR (1) AR133953A1 (es)
AU (1) AU2024351332A1 (es)
CO (1) CO2026003568A2 (es)
DO (1) DOP2026000079A (es)
IL (1) IL326819A (es)
MX (1) MX2026003030A (es)
TW (1) TW202515541A (es)
UY (1) UY40901A (es)
WO (1) WO2025068951A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026008072A1 (zh) * 2024-07-05 2026-01-08 南京正大天晴制药有限公司 补体因子b抑制剂在制备治疗或预防pnh药物中的用途
WO2026008073A1 (zh) * 2024-07-05 2026-01-08 南京正大天晴制药有限公司 补体因子b抑制剂的剂量组合物
WO2026008074A1 (zh) * 2024-07-05 2026-01-08 南京正大天晴制药有限公司 补体因子b抑制剂的晶型、其制备方法及用途
WO2026069246A1 (en) * 2024-09-30 2026-04-02 Novartis Ag Complement factor b inhibitors and uses thereof
WO2026130552A1 (zh) * 2024-12-20 2026-06-25 南京正大天晴制药有限公司 补体因子B抑制剂在制备治疗或预防IgA肾病或其相关的疾病或病症的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EP4650351A1 (en) * 2023-01-09 2025-11-19 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor of complement factor b

Also Published As

Publication number Publication date
CN121925409A (zh) 2026-04-24
UY40901A (es) 2025-04-11
CO2026003568A2 (es) 2026-06-19
KR20260079630A (ko) 2026-06-02
MX2026003030A (es) 2026-05-04
DOP2026000079A (es) 2026-04-30
EP4784563A1 (en) 2026-08-05
IL326819A (en) 2026-04-01
TW202515541A (zh) 2025-04-16
WO2025068951A1 (en) 2025-04-03
AU2024351332A1 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
UY40204A (es) Inhibidores del Factor B del Complemento y Usos de los mismos
DOP2026000079A (es) Inhibidores del factor b del complemento y usos de los mismos
DOP2024000142A (es) Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2021015318A2 (es) Compuestos y métodos para el tratamiento de covid-19
AR123685A1 (es) Antagonistas del mrgx2
CL2025000629A1 (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
DOP2021000062A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
CL2024003450A1 (es) Compuestos y usos de estos
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
AR127470A1 (es) Inhibidores de lrrk2
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CL2025000272A1 (es) Derivados de arilo tricíclico y composiciones y métodos de los mismos
CO2024009144A2 (es) Inhibidores de cinasa met
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
AR127127A1 (es) NUEVOS DERIVADOS DE PIRIDODIAZEPINAS COMO PAM DE GABAA g1
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
UY38133A (es) Nuevos inhibidores de cdk8/19